Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYPLA1 | O75608 | 1/20 | 0.50 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151506 | 0.84 | MAOB (0.51) | — | |
| SCHEMBL18782421 | 0.83 | KDM4E (0.57) | LYPLA1LYPLA2HTR1BHTR1DL3MBTL1 | |
| SCHEMBL2406190 | 0.83 | SIGMAR1 (0.39) | LYPLA1LYPLA2HTR1BHTR1DL3MBTL1 | |
| SCHEMBL12271034 | 0.82 | LYPLA1 (0.48) | LYPLA1LYPLA2HTR1BHTR1DL3MBTL1 | |
| SCHEMBL12270299 | 0.82 | ALDH1A1 (0.40) | LYPLA1LYPLA2L3MBTL1 | |
| SCHEMBL12270720 | 0.81 | LYPLA1 (0.49) | LYPLA1LYPLA2HTR1BHTR1DL3MBTL1 | |
| SCHEMBL12266251 | 0.81 | CYP1A2 (0.67) | LYPLA1LYPLA2L3MBTL1BCHEMEN1 | |
| SCHEMBL12266295 | 0.81 | LTA4H (0.51) | LYPLA1LYPLA2HTR1BHTR1DL3MBTL1 | |
| SCHEMBL12266345 | 0.81 | LYPLA1 (0.77) | LYPLA1LYPLA2LTA4HEPHX2 | |
| SCHEMBL12271043 | 0.80 | MAOB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LYPLA1 1153/4885LYPLA2 1988/4885HTR1B 2817/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | LYPLA1 4548/4885LYPLA2 4342/4885HTR1B 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.